Norepinephrine antagonists and cancer risk

International Journal of Cancer

Volumn 128, Issue 3, 2011, Pages 736-738

  Friedman, Gary D ^a   Udaltsova, Natalia ^a   Habel, Laurel A ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; CLONIDINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; METOPROLOL; NIFEDIPINE; PRAZOSIN; PROPRANOLOL; TERAZOSIN;

BREAST CANCER; CANCER PREVENTION; CANCER RISK; COLON CANCER; CONTROLLED STUDY; DRUG EXPOSURE; DRUG USE; HUMAN; LETTER; LUNG CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; TREATMENT DURATION;

EID: 78649869249     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25351     Document Type: Letter

References (7)

1. Fitzgerald PJ,. Is norepinephrine an etiological factor in some types of cancer? Int J Cancer 2009; 124: 257-63.
2. Fitzgerald PJ,. Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer. Clin Epidemiol 2010; 2: 1-3.
3. Friedman GD, Udaltsova N, Chan J, Quesenberry CP, Jr, Habel LA,. Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened. Cancer Causes Control 2009; 20: 1821-35.
4. McLaughlin JK, Lipworth L, Tarone RE, Blot WJ,. Renal cancer. In:, Schottenfeld D, Fraumeni JF, Jr,. Cancer epidemiology and prevention, 3rd ed. New York: Oxford University Press, 2006. 1087-100.
5. Ballard-Barbash R, Friedenreich C, Slattery M, Thune I,. Obesity and body composition. In:, Schottenfeld D, Fraumeni JF, Jr,. Cancer epidemiology and prevention, 3rd ed. New York: Oxford University Press, 2006. 422-48.
6. Marshall JR, Freudenheim J,. Alcohol. In:, Schottenfeld D, Fraumeni JF, Jr,. Cancer epidemiology and prevention, 3rd ed. New York: Oxford University Press, 2006. 243-58.
7. Goon PKY, Stonelake PS, Lip GYH,. Hypertension, anti-hypertensive therapy and neoplasia. Curr Pharm Des 2007; 13: 2539-44.